| 20.69 0.09 (0.44%) | 04-02 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.63 |
1-year : | 28.77 |
| Resists | First : | 21.09 |
Second : | 24.63 |
| Pivot price | 18.52 |
|||
| Supports | First : | 18.28 |
Second : | 16.54 |
| MAs | MA(5) : | 19.09 |
MA(20) : | 18.47 |
| MA(100) : | 15.3 |
MA(250) : | 11.42 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 85.1 |
D(3) : | 60.7 |
| RSI | RSI(14): 66 |
|||
| 52-week | High : | 21.09 | Low : | 4.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MNMD ] has closed It is unclear right now based on current values. 43.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 21.13 - 21.21 | 21.21 - 21.3 |
| Low: | 19.75 - 19.83 | 19.83 - 19.92 |
| Close: | 20.55 - 20.7 | 20.7 - 20.85 |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Mon, 27 Apr 2026
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect? - MSN
Fri, 27 Feb 2026
Mind Medicine Inc. (MNMD) Stock Analysis: Exploring Potential Upside in a Transformative Biotech - DirectorsTalk Interviews
Fri, 16 Jan 2026
MindMed stock soars 73% after InvestingPro’s undervalued call in May 2024 By Investing.com - Investing.com
Sat, 27 Dec 2025
What’s Driving JonesTrading’s Bullish View on Mind Medicine (MindMed) Inc. (MNMD) - Yahoo Finance
Mon, 10 Nov 2025
Will Mind Medicine (MindMed) (MNMD)'s Fresh Capital Shape a New Phase of Strategic Ambitions? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 41.6 (%) |
| Shares Short | 15,050 (K) |
| Shares Short P.Month | 12,350 (K) |
| EPS | -1.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -85.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -10.45 |
| PEG Ratio | 0 |
| Price to Book value | 12.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|